🔥 Trending Moderna and Merck Cancer Vaccine Trial Success Boosts Stock Prices
Moderna and Merck's personalized cancer vaccine, mRNA-4157 (V940), has shown promising results in a late-stage trial for melanoma, a severe form of skin cancer 1.
Significant Reduction in Melanoma Recurrence
On August 19, 2026, Moderna announced that their personalized cancer vaccine significantly reduced the recurrence of melanoma in a late-stage trial involving over 1,100 patients 1. This experimental drug also substantially extended the time patients lived without the disease returning 1.
Impact on Moderna's Stock
Following this announcement, Moderna's shares experienced a remarkable surge, increasing by 95%. This marked one of the company's best days ever on the stock market, reflecting investor confidence in the vaccine's potential 1.
Collaboration and Technology
The vaccine is a collaborative effort between Moderna and Merck. It utilizes Moderna's mRNA technology to create a personalized treatment tailored to each patient's specific tumor mutations. This approach aims to train the patient's immune system to recognize and attack cancer cells, preventing recurrence 1.
Future Outlook
The success of this late-stage trial represents a significant advancement in cancer treatment, particularly for melanoma. Further details regarding regulatory approvals and broader availability are anticipated as the companies proceed with their clinical development and submission processes.
Type your question below — talk to AI and let your chat become a new page.